OncLiveNavidea Biopharma shares fall after negative report on LymphoseekReuters(Reuters) – Navidea Biopharmaceuticals Inc’s shares fell as much as 17 percent on Friday after a negative report on TheStreet.com despite the company receiving expanded U.S. approval for its imaging agent. The U.S. Food and Drug Administration on Friday …Lymphoseek Okayed for Head-Neck Cancer UseMedPage TodayWhy Navidea Biopharmaceuticals Inc. Shares Briefly Spiked LowerMotley FoolNavidea Biopharmaceuticals (NAVB) Affirms Receipt of FDA Approval for …StreetInsider.com (subscription)Monthly Prescribing Reference -OncLive -FDA.govall 10 news articles …Read Full Story
Navidea Biopharma shares fall after negative report on Lymphoseek - Reuters
Real Estate of Cebu
